Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE Studies.

Huang DB, Noviello S, Balser B, Scaramucci A, Corey GR.

Clin Ther. 2019 Jun;41(6):1090-1096. doi: 10.1016/j.clinthera.2019.04.004. Epub 2019 Apr 25.

PMID:
31030995
2.

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.

Corey GR, McKinnell JA, Rybak MJ.

Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S191-S192. doi: 10.1093/cid/ciy1089. No abstract available.

3.

Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.

Corey GR, Wilcox MH, Gonzalez J, Jandourek A, Wilson DJ, Friedland HD, Das S, Iaconis J, Dryden M.

Int J Antimicrob Agents. 2019 Jun;53(6):830-837. doi: 10.1016/j.ijantimicag.2019.01.016. Epub 2019 Feb 1.

4.

Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.

Doernberg SB, Tran TTT, Tong SYC, Paul M, Yahav D, Davis JS, Leibovici L, Boucher HW, Corey GR, Cosgrove SE, Chambers HF, Fowler VG, Evans SR, Holland TL; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2019 May 2;68(10):1691-1698. doi: 10.1093/cid/ciy766.

PMID:
30321315
5.

Iclaprim: a differentiated option for the treatment of skin and skin structure infections.

Noviello S, Huang DB, Corey GR.

Expert Rev Anti Infect Ther. 2018 Nov;16(11):793-803. doi: 10.1080/14787210.2018.1536545. Epub 2018 Oct 23. Review.

PMID:
30317894
6.

Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe.

Huang DB, Magnet S, De Angelis S, Holland TL, File TM Jr, Dryden M, Corey GR, Torres A, Wilcox MH.

Diagn Microbiol Infect Dis. 2019 Feb;93(2):154-158. doi: 10.1016/j.diagmicrobio.2018.09.002. Epub 2018 Sep 10.

7.

Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial.

Holland TL, Raad I, Boucher HW, Anderson DJ, Cosgrove SE, Aycock PS, Baddley JW, Chaftari AM, Chow SC, Chu VH, Carugati M, Cook P, Corey GR, Crowley AL, Daly J, Gu J, Hachem R, Horton J, Jenkins TC, Levine D, Miro JM, Pericas JM, Riska P, Rubin Z, Rupp ME, Schrank J Jr, Sims M, Wray D, Zervos M, Fowler VG Jr; Staphylococcal Bacteremia Investigators.

JAMA. 2018 Sep 25;320(12):1249-1258. doi: 10.1001/jama.2018.13155.

8.

Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults.

Holland TL, Chambers HF, Boucher HW, Corey GR, Coleman R, Castaneda-Ruiz B, Fowler VG.

Clin Infect Dis. 2019 Feb 15;68(5):865-872. doi: 10.1093/cid/ciy774.

9.

Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.

Huang DB, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM Jr, Dryden M, Balser B, Desplats E, Torres A.

Int J Antimicrob Agents. 2018 Aug;52(2):233-240. doi: 10.1016/j.ijantimicag.2018.05.012. Epub 2018 May 19.

10.

A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).

Holland TL, O'Riordan W, McManus A, Shin E, Borghei A, File TM Jr, Wilcox MH, Torres A, Dryden M, Lodise T, Oguri T, Corey GR, McLeroth P, Shukla R, Huang DB.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02580-17. doi: 10.1128/AAC.02580-17. Print 2018 May.

11.

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.

Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O'Riordan W; SOLO I and SOLO II investigators.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01919-17. doi: 10.1128/AAC.01919-17. Print 2018 Apr.

12.

Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe.

Huang DB, File TM Jr, Dryden M, Corey GR, Torres A, Wilcox MH.

Diagn Microbiol Infect Dis. 2018 Apr;90(4):329-334. doi: 10.1016/j.diagmicrobio.2017.12.001. Epub 2017 Dec 7.

13.

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.

Huang DB, O'Riordan W, Overcash JS, Heller B, Amin F, File TM, Wilcox MH, Torres A, Dryden M, Holland TL, McLeroth P, Shukla R, Corey GR.

Clin Infect Dis. 2018 Apr 3;66(8):1222-1229. doi: 10.1093/cid/cix987.

14.

The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens.

Huang DB, Duncan LR, Flamm RK, Dryden M, Corey GR, Wilcox MH, Torres A, File TM Jr.

Diagn Microbiol Infect Dis. 2018 Jan;90(1):64-66. doi: 10.1016/j.diagmicrobio.2017.09.011. Epub 2017 Sep 20.

15.

A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.

Huang DB, File TM Jr, Torres A, Shorr AF, Wilcox MH, Hadvary P, Dryden M, Corey GR.

Clin Ther. 2017 Aug;39(8):1706-1718. doi: 10.1016/j.clinthera.2017.07.007. Epub 2017 Jul 27.

16.

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.

Lodise TP, Redell M, Armstrong SO, Sulham KA, Corey GR.

Open Forum Infect Dis. 2017 Jan 19;4(1):ofw274. doi: 10.1093/ofid/ofw274. eCollection 2017 Winter.

17.

Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.

Doernberg SB, Lodise TP, Thaden JT, Munita JM, Cosgrove SE, Arias CA, Boucher HW, Corey GR, Lowy FD, Murray B, Miller LG, Holland TL; Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG).

Clin Infect Dis. 2017 Mar 15;64(suppl_1):S24-S29. doi: 10.1093/cid/ciw828. Review.

18.

Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates.

Smart JI, Corey GR, Stryjewski ME, Wang W, Barriere SL.

Diagn Microbiol Infect Dis. 2017 Mar;87(3):268-271. doi: 10.1016/j.diagmicrobio.2016.12.009. Epub 2016 Dec 14.

19.

A randomized, blinded, multicenter trial of a gentamicin vancomycin gel (DFA-02) in patients undergoing abdominal surgery.

Bennett-Guerrero E, Berry SM, Bergese SD, Fleshner PR, Minkowitz HS, Segura-Vasi AM, Itani KMF, Henderson KW, Rackowski FP, Aberle LH, Stryjewski ME, Corey GR, Allenby KS.

Am J Surg. 2017 Jun;213(6):1003-1009. doi: 10.1016/j.amjsurg.2016.10.007. Epub 2016 Nov 18.

PMID:
27989501
20.

Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.

Corey GR, Arhin FF, Wikler MA, Sahm DF, Kreiswirth BN, Mediavilla JR, Good S, Fiset C, Jiang H, Moeck G, Kabler H, Green S, O'Riordan W; SOLO I, SOLO II Investigators.

Int J Antimicrob Agents. 2016 Nov;48(5):528-534. doi: 10.1016/j.ijantimicag.2016.07.019. Epub 2016 Sep 13.

PMID:
27665522
21.
22.

A randomized, double-blind, placebo controlled safety, tolerability, and pharmacokinetic dose escalation study of a gentamicin vancomycin gel in patients undergoing colorectal surgery.

Bennett-Guerrero E, Minkowitz HS, Segura-Vasi AM, Marcet JE, White JA, Corey GR, Allenby KS.

Perioper Med (Lond). 2016 Jun 16;5:17. doi: 10.1186/s13741-016-0043-2. eCollection 2016.

23.

An Approach to Improve the Negative Predictive Value and Clinical Utility of Transthoracic Echocardiography in Suspected Native Valve Infective Endocarditis.

Sivak JA, Vora AN, Navar AM, Schulte PJ, Crowley AL, Kisslo J, Corey GR, Liao L, Wang A, Velazquez EJ, Samad Z.

J Am Soc Echocardiogr. 2016 Apr;29(4):315-22. doi: 10.1016/j.echo.2015.12.009. Epub 2016 Feb 3.

24.

A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response.

Berry SM, Petzold EA, Dull P, Thielman NM, Cunningham CK, Corey GR, McClain MT, Hoover DL, Russell J, Griffiss JM, Woods CW.

Clin Trials. 2016 Feb;13(1):22-30. doi: 10.1177/1740774515621721. Epub 2016 Jan 14.

25.

Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis.

Johnson JA, Feeney ER, Kubiak DW, Corey GR.

Open Forum Infect Dis. 2015 Oct 29;2(4):ofv156. doi: 10.1093/ofid/ofv156. eCollection 2015 Dec.

26.

Building Sustainable Capacity for Cardiovascular Care at a Public Hospital in Western Kenya.

Binanay CA, Akwanalo CO, Aruasa W, Barasa FA, Corey GR, Crowe S, Esamai F, Einterz R, Foster MC, Gardner A, Kibosia J, Kimaiyo S, Koech M, Korir B, Lawrence JE, Lukas S, Manji I, Maritim P, Ogaro F, Park P, Pastakia SD, Sugut W, Vedanthan R, Yanoh R, Velazquez EJ, Bloomfield GS.

J Am Coll Cardiol. 2015 Dec 8;66(22):2550-60. doi: 10.1016/j.jacc.2015.09.086. Review.

27.

An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection.

Kauf TL, McKinnon P, Corey GR, Bedolla J, Riska PF, Sims M, Jauregui-Peredo L, Friedman B, Hoehns JD, Mercier RC, Garcia-Diaz J, Brenneman SK, Ng D, Lodise T.

BMC Infect Dis. 2015 Nov 7;15:503. doi: 10.1186/s12879-015-1261-9.

28.

Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.

Lacy MK, Stryjewski ME, Wang W, Hardin TC, Nogid B, Luke DR, Shorr AF, Corey GR, Barriere SL.

Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S87-93. doi: 10.1093/cid/civ536.

PMID:
26316562
29.

Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance.

Pushkin R, Barriere SL, Wang W, Corey GR, Stryjewski ME.

Antimicrob Agents Chemother. 2015 Oct;59(10):6170-4. doi: 10.1128/AAC.00471-15. Epub 2015 Jul 27.

30.

New developments in the management of severe skin and deep skin structure infections - focus on tedizolid.

Durkin MJ, Corey GR.

Ther Clin Risk Manag. 2015 May 22;11:857-62. doi: 10.2147/TCRM.S64553. eCollection 2015. Review.

31.

Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis.

Thom H, Thompson JC, Scott DA, Halfpenny N, Sulham K, Corey GR.

Curr Med Res Opin. 2015 Aug;31(8):1539-51. doi: 10.1185/03007995.2015.1058248. Epub 2015 Jun 30. Review.

PMID:
26038985
32.

Reply to Solnick.

Corey GR, Stryjewski ME.

Clin Infect Dis. 2015 Aug 1;61(3):485-6. doi: 10.1093/cid/civ372. Epub 2015 May 8. No abstract available.

PMID:
25956892
33.

A closer inspection of tedizolid - authors' reply.

Prokocimer P, Corey GR, Das AF, Moran GJ.

Lancet Infect Dis. 2015 Apr;15(4):375. doi: 10.1016/S1473-3099(15)70103-9. No abstract available.

PMID:
25809888
34.

Oritavancin for acute bacterial skin and skin structure infections.

Messina JA, Fowler VG Jr, Corey GR.

Expert Opin Pharmacother. 2015 May;16(7):1091-8. doi: 10.1517/14656566.2015.1026256. Epub 2015 Mar 24. Review.

35.

Reply to DiNubile.

Corey GR, Boucher HW, Stryjewski ME.

Clin Infect Dis. 2015 Apr 15;60(8):1291-2. doi: 10.1093/cid/civ025. Epub 2015 Jan 21. No abstract available.

PMID:
25609681
36.

Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.

Stryjewski ME, Jones RN, Corey GR.

Diagn Microbiol Infect Dis. 2015 Mar;81(3):183-8. doi: 10.1016/j.diagmicrobio.2014.11.016. Epub 2014 Dec 3. Review.

PMID:
25583130
37.

An integrated transcriptome and expressed variant analysis of sepsis survival and death.

Tsalik EL, Langley RJ, Dinwiddie DL, Miller NA, Yoo B, van Velkinburgh JC, Smith LD, Thiffault I, Jaehne AK, Valente AM, Henao R, Yuan X, Glickman SW, Rice BJ, McClain MT, Carin L, Corey GR, Ginsburg GS, Cairns CB, Otero RM, Fowler VG Jr, Rivers EP, Woods CW, Kingsmore SF.

Genome Med. 2014 Nov 26;6(11):111. doi: 10.1186/s13073-014-0111-5. eCollection 2014.

38.

Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.

Corey GR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL.

Clin Infect Dis. 2015 Mar 1;60(5):787-96. doi: 10.1093/cid/ciu971. Epub 2014 Dec 3. Review.

39.

Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.

Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, Prokocimer P.

Antimicrob Agents Chemother. 2015 Feb;59(2):864-71. doi: 10.1128/AAC.03688-14. Epub 2014 Nov 24.

40.

Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study.

Chirouze C, Alla F, Fowler VG Jr, Sexton DJ, Corey GR, Chu VH, Wang A, Erpelding ML, Durante-Mangoni E, Fernández-Hidalgo N, Giannitsioti E, Hannan MM, Lejko-Zupanc T, Miró JM, Muñoz P, Murdoch DR, Tattevin P, Tribouilloy C, Hoen B; ICE Prospective Investigators.

Clin Infect Dis. 2015 Mar 1;60(5):741-9. doi: 10.1093/cid/ciu871. Epub 2014 Nov 10.

41.

Editorial commentary: NOVA score to predict endocarditis in patients with enterococcal bacteremia: sticking to valves or to scores?

Stryjewski ME, Corey GR.

Clin Infect Dis. 2015 Feb 15;60(4):536-8. doi: 10.1093/cid/ciu878. Epub 2014 Nov 7. No abstract available.

PMID:
25381322
42.

Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, Manos P, Keech R, Singh R, Heller B, Bubnova N, O'Riordan W; SOLO II Investigators.

Clin Infect Dis. 2015 Jan 15;60(2):254-62. doi: 10.1093/cid/ciu778. Epub 2014 Oct 6.

PMID:
25294250
43.

Dalbavancin or oritavancin for skin infections.

Corey GR, Jiang H, Moeck G.

N Engl J Med. 2014 Sep 18;371(12):1162-3. doi: 10.1056/NEJMc1407925. No abstract available.

PMID:
25243251
44.

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P.

Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5.

PMID:
24909499
45.

Single-dose oritavancin in the treatment of acute bacterial skin infections.

Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, Lucasti C, Perez A, Good S, Jiang H, Moeck G, O'Riordan W; SOLO I Investigators.

N Engl J Med. 2014 Jun 5;370(23):2180-90. doi: 10.1056/NEJMoa1310422.

46.

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.

Stryjewski ME, Lentnek A, O'Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG Jr, Barriere SL, Kitt MM, Corey GR.

BMC Infect Dis. 2014 May 23;14:289. doi: 10.1186/1471-2334-14-289.

47.
48.

Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.

Corey GR, Kollef MH, Shorr AF, Rubinstein E, Stryjewski ME, Hopkins A, Barriere SL.

Antimicrob Agents Chemother. 2014;58(4):2030-7. doi: 10.1128/AAC.02330-13. Epub 2014 Jan 13. Erratum in: Antimicrob Agents Chemother. 2014 Jun;58(6):3581.

49.

Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.

Torres A, Rubinstein E, Corey GR, Stryjewski ME, Barriere SL.

J Antimicrob Chemother. 2014 Apr;69(4):1119-26. doi: 10.1093/jac/dkt490. Epub 2014 Jan 6.

50.

Methicillin-resistant Staphylococcus aureus: an evolving pathogen.

Stryjewski ME, Corey GR.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S10-9. doi: 10.1093/cid/cit613. Review.

PMID:
24343827

Supplemental Content

Loading ...
Support Center